These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 22809706)

  • 21. Treating nicotine dependence by targeting attention-deficit/ hyperactivity disorder (ADHD) with OROS methylphenidate: the role of baseline ADHD severity and treatment response.
    Nunes EV; Covey LS; Brigham G; Hu MC; Levin FR; Somoza EC; Winhusen TM
    J Clin Psychiatry; 2013 Oct; 74(10):983-90. PubMed ID: 24229749
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safe and effective methylphenidate therapy in a pediatric patient with glaucoma.
    Lewis H; Lewis J
    Atten Defic Hyperact Disord; 2012 Mar; 4(1):37-9. PubMed ID: 22311620
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder.
    Medori R; Ramos-Quiroga JA; Casas M; Kooij JJ; Niemelä A; Trott GE; Lee E; Buitelaar JK
    Biol Psychiatry; 2008 May; 63(10):981-9. PubMed ID: 18206857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
    Moungnoi P; Maipang P
    J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S158-63. PubMed ID: 22043770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): changes in the consumption pattern following the introduction of extended release methylphenidate.
    Treceño C; Martín Arias LH; Sáinz M; Salado I; García Ortega P; Velasco V; Jimeno N; Escudero A; Velasco A; Carvajal A
    Pharmacoepidemiol Drug Saf; 2012 Apr; 21(4):435-41. PubMed ID: 22253017
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictive factors for more than 3 years' duration of central stimulant treatment in adult attention-deficit/hyperactivity disorder: a retrospective, naturalistic study.
    Torgersen T; Gjervan B; Nordahl HM; Rasmussen K
    J Clin Psychopharmacol; 2012 Oct; 32(5):645-52. PubMed ID: 22926598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transitioning to OROS(®) methylphenidate from atomoxetine is effective in children and adolescents with ADHD.
    Niederkirchner K; Slawik L; Wermelskirchen D; Rettig K; Schäuble B
    Expert Rev Neurother; 2011 Apr; 11(4):499-508. PubMed ID: 21469923
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Twenty-four-week treatment with extended release methylphenidate improves emotional symptoms in adult ADHD.
    Rösler M; Retz W; Fischer R; Ose C; Alm B; Deckert J; Philipsen A; Herpertz S; Ammer R
    World J Biol Psychiatry; 2010 Aug; 11(5):709-18. PubMed ID: 20353312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of transitioning from extended-release methylphenidate onto osmotic, controlled-release methylphenidate in children/adolescents with ADHD: results of a 3-month non-interventional study.
    Wolff C; Alfred A; Lindermüller A; Rettig K; Mattejat F; Gerwe M; Slawik L; Schäuble B
    Curr Med Res Opin; 2011; 27 Suppl 2():35-44. PubMed ID: 21787126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does placebo response differ between objective and subjective measures in children with attention-deficit/hyperactivity disorder?
    Sumner CR; Haynes VS; Teicher MH; Newcorn JH
    Postgrad Med; 2010 Sep; 122(5):52-61. PubMed ID: 20861588
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-Term Treatment Outcome in Adult Male Prisoners With Attention-Deficit/Hyperactivity Disorder: Three-Year Naturalistic Follow-Up of a 52-Week Methylphenidate Trial.
    Ginsberg Y; Långström N; Larsson H; Lindefors N
    J Clin Psychopharmacol; 2015 Oct; 35(5):535-43. PubMed ID: 26284932
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tolerability and effects of OROS® MPH (Concerta ®) on functioning, severity of disease and quality of life in children and adolescents with ADHD: results from a prospective, non-interventional trial.
    Gerwe M; Stollhoff K; Mossakowski J; Kuehle HJ; Goertz U; Schaefer C; Bogdanow M; Heger S
    Atten Defic Hyperact Disord; 2009 Dec; 1(2):175-86. PubMed ID: 21432582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring longitudinal course and treatment-baseline severity interactions in secondary outcomes of smoking cessation treatment in individuals with attention-deficit hyperactivity disorder.
    Luo SX; Wall M; Covey L; Hu MC; Scodes JM; Levin FR; Nunes EV; Winhusen T
    Am J Drug Alcohol Abuse; 2018; 44(6):653-659. PubMed ID: 29370538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A controlled trial of methylphenidate in adults with attention deficit/hyperactivity disorder and substance use disorders.
    Carpentier PJ; de Jong CA; Dijkstra BA; Verbrugge CA; Krabbe PF
    Addiction; 2005 Dec; 100(12):1868-74. PubMed ID: 16367988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of comorbid autism spectrum disorders on stimulant response in children with attention deficit hyperactivity disorder: a retrospective and prospective effectiveness study.
    Santosh PJ; Baird G; Pityaratstian N; Tavare E; Gringras P
    Child Care Health Dev; 2006 Sep; 32(5):575-83. PubMed ID: 16919137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The reinforcing effects of nicotine and stimulant medication in the everyday lives of adult smokers with ADHD: A preliminary examination.
    Gehricke JG; Whalen CK; Jamner LD; Wigal TL; Steinhoff K
    Nicotine Tob Res; 2006 Feb; 8(1):37-47. PubMed ID: 16497598
    [TBL] [Abstract][Full Text] [Related]  

  • 38. OROS methylphenidate in the treatment of adults with ADHD: a 6-month, open-label, follow-up study.
    Marchant BK; Reimherr FW; Halls C; Williams ED; Strong RE
    Ann Clin Psychiatry; 2010 Aug; 22(3):196-204. PubMed ID: 20680193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential Posttreatment Outcomes of Methylphenidate for Smoking Cessation for Individuals With ADHD.
    Luo SX; Covey LS; Hu MC; Winhusen TM; Nunes EV
    Am J Addict; 2019 Nov; 28(6):497-502. PubMed ID: 31538372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Attention-deficit/hyperactivity disorder with obstructive sleep apnea: a treatment outcome study.
    Huang YS; Guilleminault C; Li HY; Yang CM; Wu YY; Chen NH
    Sleep Med; 2007 Jan; 8(1):18-30. PubMed ID: 17157069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.